/**/ RNS Number : 4520X IQ-AI Limited 26 April 2023   26 April 2023   IQ-AI Ltd (“IQ-AI” or the “Company”)   Publication of Annual Report   The Board of IQ-AI Ltd is pleased to announce the Company’s audited financial statements for the year ended 31 December 2022.   The Annual Report will be available…

Read more . . .

/**/ RNS Number : 3886R IQ-AI Limited 28 February 2023   IQ-AI Announces Orphan Drug Designation Status FDA grants orphan status to Gallium Maltolate for treating GBM IQ-AI Limited, (LSE: IQAI) (OTCQB: IQAIF), is pleased to announce that the United States Food and Drug Administration (FDA) has granted orphan drug designation (ODD) status for gallium…

Read more . . .

/**/ RNS Number : 1496M IQ-AI Limited 10 January 2023   IQ-AI LIMITED ISSUES LETTER TO SHAREHOLDERS   IQ-AI Limited (“IQAI”) (LSE: IQAI) (OTCQB: IQAIF) a developer and manufacturer of medical image processing platforms, has today released a letter to shareholders on behalf of Michael Schmainda, CEO of IQ-AI’s wholly-owned subsidiary Imaging Biometrics (the “Company”), covering several material…

Read more . . .

/**/ RNS Number : 4535I IQ-AI Limited 02 December 2022   TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to…

Read more . . .

/**/ RNS Number : 2244B IQ-AI Limited 30 September 2022   IQ-AI LIMITED ISSUES LETTER TO SHAREHOLDERS   Imaging Biometrics, a subsidiary of IQ-AI Limited (OTCQB: IQAIF: LSE: IQAI), summarises the Company’s achievements in 2022 to date, which includes: ·      Company focuses on deployment of IB Clinic™ ·      IB NIMBLE™ connects experts to help treat…

Read more . . .